Galderma wins China approval for Relfydess after positive Phase 3 frown line results. Competition and its pending US review remain crucial.
China's NMPA has authorized clinical investigation of NW001, a PD-L1-targeted antibody conjugate carrying a histone deacetylase inhibitor. Chipscreen reports activity in checkpoint-resistant preclinical cancer models, but human safety, dosing and efficacy remain unestablished.
Foresee's CAMCEVI 42 mg wins China approval for advanced prostate cancer. Examine GeneScience's launch plans, clinical evidence and licensing economics.
Chipscreen secures China IND clearance for CS43158, targeting FLT3 mutations and resistance pathways in acute myeloid leukemia.
Rani Therapeutics Holdings, Inc. and PegBio Co., Ltd. have formed a research and development collaboration to evaluate whether several injectable obesity and metabolic disease candidates can be delivered through Rani Therapeutics’ swallowable RaniPill platform. The partners plan to screen oral formulations, complete preclinical development and select the most promising programmes for possible advancement into human
Hansoh Pharmaceutical Group Co., Ltd. has reported that risvutatug rezetecan, also known as Ris-Rez or HS-20093, significantly improved overall survival in the pivotal Phase 3 ARTEMIS-008 trial involving Chinese patients with advanced or relapsed small-cell lung cancer following platinum-based treatment. The B7-H3-directed antibody-drug conjugate was compared with topotecan and also produced a consistent benefit in
MindRank AI Ltd. has completed a $52 million Series B financing to advance its artificial intelligence-led drug research platform and a clinical pipeline headed by MDR-001, an oral small-molecule glucagon-like peptide-1 receptor agonist already in Phase 3 development in China. The Hangzhou-based biotechnology company said the financing was led by a group of institutional and
Find out how Akeso’s gumokimab approval could reshape China’s psoriasis biologics market and IL-17 competition.
Leqembi’s Alzheimer’s rollout is still slow, but Eisai’s 2028 sales simulation keeps BioArctic’s royalty story alive.
Lupin’s China debut starts with flu medicine. The bigger story is whether one approval can open a larger paediatric pharma pathway.